Uncategorized
Aerie Pharmaceuticals Reports Update on Positive Safety Results for RhopressaTM QD (netarsudil ophthalmic solution) 0.02%
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported an update including further details on the safety profile for RhopressaTM QD, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The Company previously reported interim topline 1
